These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17467344)

  • 1. Selection of pfmdr1 mutations after amodiaquine monotherapy and amodiaquine plus artemisinin combination therapy in East Africa.
    Holmgren G; Hamrin J; Svärd J; Mårtensson A; Gil JP; Björkman A
    Infect Genet Evol; 2007 Sep; 7(5):562-9. PubMed ID: 17467344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased prevalence of Plasmodium falciparum resistance markers to amodiaquine despite its wide scale use as ACT partner drug in Zanzibar.
    Fröberg G; Jörnhagen L; Morris U; Shakely D; Msellem MI; Gil JP; Björkman A; Mårtensson A
    Malar J; 2012 Sep; 11():321. PubMed ID: 22966778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate-amodiaquine fixed dose combination or artemether-lumefantrine in Liberia.
    Otienoburu SD; Maïga-Ascofaré O; Schramm B; Jullien V; Jones JJ; Zolia YM; Houzé P; Ashley EA; Kiechel JR; Guérin PJ; Le Bras J; Houzé S
    Malar J; 2016 Sep; 15(1):452. PubMed ID: 27596849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SELECTION OF PFCRT 76T AND PFMDR1 86Y MUTANT PLASMODIUM FALCIPARUM AFTER TREATMENT OF UNCOMPLICATED MALARIA WITH ARTESUNATE-AMODIAQUINE IN REPUBLIC OF GUINEA.
    Beavogui AH; Diawara EY; Cherif MS; Delamou A; Diallo N; Traore A; Millimouno P; Camara D; Sylla MM; Toure AA; Diallo MS; Toure S; Togo A; Camara G; Kourouma K; Sagara I; Dicko A; Djimde A
    J Parasitol; 2021 Sep; 107(5):778-782. PubMed ID: 34581793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of Plasmodium falciparum anti-malarial resistance-associated polymorphisms in pfcrt, pfmdr1 and pfnhe1 in Muheza, Tanzania, prior to introduction of artemisinin combination therapy.
    Gadalla NB; Tavera G; Mu J; Kabyemela ER; Fried M; Duffy PE; Sá JM; Wellems TE
    Malar J; 2015 Mar; 14():129. PubMed ID: 25890383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular monitoring of Plasmodium falciparum drug susceptibility at the time of the introduction of artemisinin-based combination therapy in Yaoundé, Cameroon: implications for the future.
    Menard S; Morlais I; Tahar R; Sayang C; Mayengue PI; Iriart X; Benoit-Vical F; Lemen B; Magnaval JF; Awono-Ambene P; Basco LK; Berry A
    Malar J; 2012 Apr; 11():113. PubMed ID: 22498364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro amodiaquine resistance and its association with mutations in pfcrt and pfmdr1 genes of Plasmodium falciparum isolates from Nigeria.
    Folarin OA; Bustamante C; Gbotosho GO; Sowunmi A; Zalis MG; Oduola AM; Happi CT
    Acta Trop; 2011 Dec; 120(3):224-30. PubMed ID: 21920347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y.
    Holmgren G; Gil JP; Ferreira PM; Veiga MI; Obonyo CO; Björkman A
    Infect Genet Evol; 2006 Jul; 6(4):309-14. PubMed ID: 16271310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. falciparum samples during 2008-2011.
    Eyase FL; Akala HM; Ingasia L; Cheruiyot A; Omondi A; Okudo C; Juma D; Yeda R; Andagalu B; Wanja E; Kamau E; Schnabel D; Bulimo W; Waters NC; Walsh DS; Johnson JD
    PLoS One; 2013; 8(5):e64299. PubMed ID: 23675533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda.
    Nsobya SL; Dokomajilar C; Joloba M; Dorsey G; Rosenthal PJ
    Antimicrob Agents Chemother; 2007 Aug; 51(8):3023-5. PubMed ID: 17562798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria.
    Humphreys GS; Merinopoulos I; Ahmed J; Whitty CJ; Mutabingwa TK; Sutherland CJ; Hallett RL
    Antimicrob Agents Chemother; 2007 Mar; 51(3):991-7. PubMed ID: 17194834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of pfmdr1 and pfcrt alleles in amodiaquine treatment failure in north-western Burkina Faso.
    Danquah I; Coulibaly B; Meissner P; Petruschke I; Müller O; Mockenhaupt FP
    Acta Trop; 2010 Apr; 114(1):63-6. PubMed ID: 20060374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vivo efficacy of amodiaquine-artesunate in children with uncomplicated Plasmodium falciparum malaria in western Kenya.
    Thwing JI; Odero CO; Odhiambo FO; Otieno KO; Kariuki S; Ord R; Roper C; McMorrow M; Vulule J; Slutsker L; Newman RD; Hamel MJ; Desai M
    Trop Med Int Health; 2009 Mar; 14(3):294-300. PubMed ID: 19187521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Plasmodium falciparum anti-malarial drug resistance markers in pfk13-propeller, pfcrt and pfmdr1 genes in isolates from treatment failure patients in Democratic Republic of Congo, 2018-2019.
    Yobi DM; Kayiba NK; Mvumbi DM; Boreux R; Kabututu PZ; Situakibanza HNT; Umesumbu SE; De Mol P; Speybroeck N; Mvumbi GL; Hayette MP
    Malar J; 2021 Mar; 20(1):144. PubMed ID: 33706773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso.
    Sondo P; Derra K; Diallo Nakanabo S; Tarnagda Z; Kazienga A; Zampa O; Valéa I; Sorgho H; Owusu-Dabo E; Ouédraogo JB; Guiguemdé TR; Tinto H
    PLoS One; 2016; 11(3):e0151565. PubMed ID: 27031231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmodium falciparum Polymorphisms associated with ex vivo drug susceptibility and clinical effectiveness of artemisinin-based combination therapies in Benin.
    Dahlström S; Aubouy A; Maïga-Ascofaré O; Faucher JF; Wakpo A; Ezinmègnon S; Massougbodji A; Houzé P; Kendjo E; Deloron P; Le Bras J; Houzé S
    Antimicrob Agents Chemother; 2014; 58(1):1-10. PubMed ID: 24100489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data.
    Bretscher MT; Dahal P; Griffin J; Stepniewska K; Bassat Q; Baudin E; D'Alessandro U; Djimde AA; Dorsey G; Espié E; Fofana B; González R; Juma E; Karema C; Lasry E; Lell B; Lima N; Menéndez C; Mombo-Ngoma G; Moreira C; Nikiema F; Ouédraogo JB; Staedke SG; Tinto H; Valea I; Yeka A; Ghani AC; Guerin PJ; Okell LC
    BMC Med; 2020 Feb; 18(1):47. PubMed ID: 32098634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso.
    Somé AF; Séré YY; Dokomajilar C; Zongo I; Rouamba N; Greenhouse B; Ouédraogo JB; Rosenthal PJ
    Antimicrob Agents Chemother; 2010 May; 54(5):1949-54. PubMed ID: 20231394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemisinin.
    Njokah MJ; Kang'ethe JN; Kinyua J; Kariuki D; Kimani FT
    Malar J; 2016 Jul; 15(1):381. PubMed ID: 27449110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda.
    Nawaz F; Nsobya SL; Kiggundu M; Joloba M; Rosenthal PJ
    J Infect Dis; 2009 Dec; 200(11):1650-7. PubMed ID: 19905933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.